Drug and chemical firms relax patent controls for COVID-19 response
Thursday, May 14, 2020 - 20:10
in Mathematics & Economics
Gilead offers royalty-free licenses on remdesivir, consortium pledges not to prosecute IP violations done to fight the pandemic